Effects of a Novel Nitroxyl Donor in Acute Heart Failure
نویسندگان
چکیده
The primary objective was to identify well-tolerated doses of cimlanod in patients with acute heart failure (AHF). Secondary objectives were signals efficacy, including biomarkers, symptoms, and clinical events. Nitroxyl (HNO) donors have vasodilator, inotropic lusitropic effects. Bristol-Myers Squibb-986231 (cimlanod) is an HNO donor being developed for This a phase IIb, double-blind, randomized, placebo-controlled trial 48-h treatment compared placebo left ventricular ejection fraction ≤40% hospitalized AHF. In part I, randomized 1:1 ratio escalating or matching placebo. II, 1:1:1 either the 2 highest tolerated from I endpoint rate clinically relevant hypotension (systolic blood pressure <90 mm Hg became symptomatic). (n = 100), more common than (20% vs. 8%; relative risk [RR]: 2.45; 95% confidence interval [CI]: 0.83 14.53). II 222), incidence 18% placebo, 21% 6 μg/kg/min (RR: 1.15; CI: 0.58 2.43), 35% 12 1.9; 1.04 3.59). N-terminal pro–B-type natriuretic peptide bilirubin decreased during infusion but these differences did not persist after discontinuation. Cimlanod at dose reasonably reduced markers congestion, this beyond period. (Evaluate Safety Efficacy 48-Hour Infusions (Nitroxyl) Donor Hospitalized Patients With Heart Failure [STANDUP AHF]; NCT03016325)
منابع مشابه
Nitroxyl (HNO): A novel approach for the acute treatment of heart failure.
BACKGROUND The nitroxyl (HNO) donor, Angeli's salt, exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent. Its clinical usefulness is limited by chemical instability and cogeneration of nitrite which itself has vascular effects. Here, we report on effects of a novel, stable, pure HNO donor (CXL-1020) in isolated myoctyes and intact hearts in experiment...
متن کاملNitroxyl, redox switches, cardiac myofilaments, and heart failure: a prequel to novel therapeutics?
متن کامل
tolvaptan: a novel diuretic in heart failure management
heart failure (hf) is still a major problem worldwide with high morbidity and mortality rates. the recently developed medication for hf is still incapable of reducing its morbidity and mortality, and clinical data supporting the efficacy and safety of its mainstay therapy remain insufficient. arginine-vasopressin (avp) plays important roles in circulatory and water homeostasis, one of which is ...
متن کاملGender Effects on Acute Heart Failure
Background: congestive heart failure is the leading cause of hospitalization in the elderly. Little is known about gender effect on baseline characteristics and in-hospital outcome in patients admitted with acute heart failure. Our purpose was to study the gender effect on in-hospital mortality in acute heart failure patients. Methods and Results: a prospective study [143 patients, 67 men (73.9...
متن کاملCONGESTIVE HEART FAILURE IN CHILDREN: A SURVEY OF 114 PATIENTS
During a period of four years between June, IS, 1988 to June, IS, 1992 one hundred and fourteen patients with congestive heart failure (CHF) were admitted to the pediatric department of Taleghani General Hospital. During the above period, 192 patients with heart disease were hospitalized at this department and CHF was the cause of admission in 59.4% of them. Congenital heart disease (CHO) w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Jacc-Heart Failure
سال: 2021
ISSN: ['2213-1787', '2213-1779']
DOI: https://doi.org/10.1016/j.jchf.2020.10.012